Results 61 to 70 of about 396 (132)

Somapacitan Is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: A Randomized Controlled Phase 3 Study.

Horm Res Paediatr
Introduction: REAL6 is a randomized, multi-centre, open-labelled, active-controlled parallel group phase 3 trial (NCT04970654) investigating once-weekly somapacitan, a reversible albumin-binding growth hormone (GH) derivative, in Chinese children with GH deficiency (GHD). Methods: 110 treatment-naïve patients were randomized 2:1 to somapacitan (0.16 mg/
Fu J, Cheng X, Højby M, Gong C, Leunbach TL, Li Y, Wei H, Zhu Y, Zhang Y, Zhong Y.   +9 more
europepmc   +3 more sources

Annual banned‐substance review 16th edition—Analytical approaches in human sports drug testing 2022/2023

Drug Testing and Analysis, Volume 16, Issue 1, Page 5-29, January 2024.
Abstract In this 16th edition of the annual banned‐substance review on analytical approaches in human sports drug testing, literature on recent developments in this particular section of global anti‐doping efforts that was published between October 2022 and September 2023 is summarized and discussed.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Supplementary materials for "Gene expression signatures predict first-year response to somapacitan treatment in children with GH deficiency"

Supplementary material for "Gene expression signatures predict first-year response to somapacitan treatment in children with GH deficiency"
Terence Garner (10631333), Philip Murray (17354734), Peter Clayton (17354725), Michael Højby Rasmussen (14699299), Adam Stevens (17354737)   +4 more
core   +1 more source

Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial

European Journal of Endocrinology
Abstract Objective Daily growth hormone (GH) injections are indicated for the treatment of short stature in children with Noonan syndrome, which presents a treatment burden for the child and their parents/caregivers.
Alexander A L Jorge, Assunta Albanese, Michael Højby, Kamil Soltysik, Thomas Edouard, Anna Grandone, Michael Tansey, Jun Mori   +7 more
openaire   +3 more sources

Expérience en ville réelle du somapacitan au CHU de Nantes

Annales d'Endocrinologie
S. Soueidan, P. Mahot, M. Ollivier, C. Sollier, M. Le Bras, E. Landau, A. Colombel, D. Drui   +7 more
openaire   +2 more sources

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

Frontiers in Endocrinology, 2023
Martin Bidlingmaier, Beverly M.K. Biller, David Clemmons, Jens Otto L. Jørgensen, Hiroshi Nishioka, Yutaka Takahashi, Yutaka Takahashi   +6 more
doaj   +1 more source

6731 Initial therapeutic effects of weekly growth hormone replacement therapy: somapacitan [PDF]

J Endocr Soc
Abstract Disclosure: S. Fujio: None. R. Makino: None. J. Sugata: None. T. Hanada: None. R. Hanaya: None. Introduction: In Japan, the restriction on the administration of somapacitan, a long-acting growth hormone (GH) analogue, was lifted in December 2022, allowing the drug to be administered to many patients with severe ...
Fujio, S, Makino, R, Sugata, J, Hanada, T, Hanaya, R   +4 more
europepmc   +2 more sources

Seven-year safety and efficacy of somapacitan in children with GH deficiency

Background: Somapacitan is a once-weekly GH treatment that has shown efficacy and safety profiles equivalent to daily GH in children with GH deficiency (GHD). Objective: To investigate long-term safety, efficacy, and treatment burden associated with somapacitan after 7 years (364 weeks) of treatment.
Sävendahl, Lars, Battelino, Tadej, Højby Rasmussen, Michael, Leunbach, Tina, Saenger, Paul, Silverman, Lawrence, Horikawa, Reiko   +6 more
openaire   +1 more source

Facts and news about growth hormone replacement therapy in adults

International audienceAdult growth hormone deficiency (GHD) is associated with increased adiposity, reduced lean mass, adverse lipid profile, decreased bone density and impaired quality of life.
Brue, Thierry, Aouchiche, Karine, Piazzola, Cécilia, Castinetti, Frédéric, Morange, Isabelle, Vermalle, Marie, Albarel, Frédérique, Sahakian, Nicolas, Cuny, Thomas   +8 more
core   +1 more source

Somapacitan-Beco: For Adult Human Growth Hormone Deficiency

Journal of Medical Science And clinical Research, 2020
openaire   +1 more source